EFFECTS OF ANTICOAGULATION THERAPY WITH VITAMIN K ANTAGONISTS ON HOSPITALIZATIONS AND EMERGENCY ROOM ACCESSES IN GROSSETO (ITALY) by Troiano, Gianmarco
E88
Introduction. A lot of drug groups are associated with prevent-
able drug-related admissions. Coumarin derivatives, prescribed 
for the treatment and prevention of deep vein thrombosis or pul-
monary embolism or prevention of systemic embolism or stroke 
in patients with prosthetic heart valves or atrial fibrillation, are 
often associated with bleeding. The aim of our study was to ana-
lyze how the anticoagulant therapy with VKAs could affects the 
hospitalizations and the visits to emergency room in the elderly 
population (> 65 years old).
Methods. In 2013 we conducted a cross sectional study analyzing 
the database of all pharmaceutical prescriptions, selecting patients 
living in Grosseto (Italy), which received at least two prescriptions 
of coumarin derivatives in 2012. We analyzed the admissions to 
hospital and the accesses to the emergency rooms (ERs) made by 
each patient, focusing especially on those related to bleeding. For 
each access to ER we recorded the date, time of stay, diagnosis 
and outcome. For each hospitalization the information we recorded 
were the date of admission and discharge diagnosis.
Results. 3684 patients were included in our study. 261 (7.1%) 
patients visited the emergency room for bleeding; 37 (1%) for 
intracranial bleeding. The accesses made by men were higher 
than those made by women. The average time of stay in ER was 
349 minutes. The admissions to hospital were 96 (2.6%); 42 
(1.1%) were admitted to hospital with a diagnosis of major vascu-
lar event. 53 patients (20.3%), accessed to the ER more than one 
time. The 11.5% was admitted to the hospital more than one time. 
Conclusions. Our study showed that VKAs are responsible of an 
increase of the accesses to ER and of the admissions to hospital. 
However, it would be interesting to enlarge the sample size includ-
ing patients living in other provinces or in other regions, with a 
lower age and treated also with TSOACs, in order to evaluate the 
real cost-effectiveness of anticoagulant therapy.
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Introduction
The World Health Organization has defined pharma-
covigilance as “the science and activities relating to the 
detection, assessment, understanding, and prevention of 
adverse effects or any other drug-related problems” [1].
Such “drug-related problems” include adverse drug re-
actions (ADRs), unintended injuries or complications 
that arise from iatrogenic drug related causes and which 
cause or prolong hospital admission and result in dis-
ability or death  [2-4]. The risk of ADRs is necessarily 
an inherent risk of all drug therapy and is modulated by 
several factors, including dose and frequency of admin-
istration, genotype, and pharmacokinetic characteristics 
of special populations, such as pediatric and geriatric pa-
tients and those with hepatic or renal impairment. Due to 
the high frequency and potentially serious consequences, 
ADRs may have a dramatic impact in clinical practice 
both from a clinical and economic perspective  [5]. As 
described by Formenti et al. in their study [6] the onset 
of adverse reactions (ADRs) represents a sentinel event 
and, in addition to diminishing the quality of life of the 
patient increases the number of medical visits, hospi-
talizations and even the deaths, resulting in an overall 
increase in health care costs. Containing the number of 
ADRs, therefore, would result in a cost reduction for the 
ADRs treatment, diagnostic examinations and differen-
tial diagnosis analysis [7-9]. 
Estimates from France suggest that up to 123,000 pa-
tients a year present to their general practitioner with 
an ADRs  [10]. ADRs account for 4.2-30% of hospital 
admissions in the USA and Canada, 5.7-18.8% of ad-
missions in Australia, and 2.5-10.6% of admissions in 
Europe [8].
A national study from the USA estimated that 11.4-
35.5% of emergency department visits in older adults 
are due to drug-related causes [5, 11].
Howard et al.  [8] showed in their systematic review 
that the drug groups most frequently associated with 
all types of preventable drug-related admissions were 
antiplatelets, diuretics, nonsteroidal anti-inflammatory 
drugs (NSAIDs) and anticoagulants.
Coumarin derivatives, such as warfarin, acenocoumarol 
and phenprocoumon are prescribed for different indi-
cations such as treatment and prevention of deep vein 
thrombosis or pulmonary embolism or prevention of 
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systemic embolism or stroke in patients with prosthetic 
heart valves or atrial fibrillation [12]. Because warfarin 
and other coumarin derivatives inhibit the vitamin K de-
pendent synthesis of biologically active clotting factors, 
they are also called vitamin K antagonists (VKAs). The 
main adverse effect associated with coumarin deriva-
tives is bleeding. Several studies have shown that the in-
cidence of major bleeding in patients on warfarin ranges 
from 0.4%-7.2% per year [13]. Minor bleeding rates can 
be as high as 15.4% per year [14]. Fatal bleeding events 
occur at rates of 1.3 per 100 patient-years, according to 
a meta-analysis of 33 studies [15]. 
However in different studies is not always used the 
same definitions, methods, and consequently, the re-
sults vary a lot; moreover the follow-up time is vari-
able and often the studies focus only on a category 
of patients. The aim of our study was to analyze the 
impact of the anticoagulant therapy with VKAs in the 
elderly population – over 65 years old, defined accord-
ing to the World Health Organization definition of “el-
derly person”  [16, 17] –, through the hospitalizations 
and the visits to emergency room, using only current 
data flows. This kind of analysis let us to analyze this 
phenomenon in a “real setting”, in order to quantify 
the impact of the side effects in a not selected sample, 
with co-morbidities, with advanced age and with pos-
sible problems of compliance with therapy. This is par-
ticularly interesting for anticoagulants which are often 
used in old people with a lot of pathologies, and often 
living in not adequate domestic environments.
Methods
In 2013 we conducted a cross sectional study in the De-
mographic and Epidemiological System of the AUSL 
Toscana Sud Est. We analyzed the database of all phar-
maceutical prescriptions: this is a database containing 
all the information about the loanable pharmaceutical 
prescriptions, derived from the flows directed to the Na-
tional Health System. 
We selected patients living in Grosseto – Italy, total resi-
dent population: 223,652 [18] –, which received at least 
two prescriptions of VKAs in 2012. This selection was 
chosen in order to identify patients subjected to long 
term therapy with anticoagulants. We collected informa-
tion about age, gender, type of medication, city of resi-
dence. Then, through a unique identification code, we 
identified and analyzed the admissions to hospital (we 
considered the admissions to all Italian hospitals) and 
the accesses to the emergency rooms (ER – we consid-
ered the ERs of Grosseto, Castel del Piano, Orbetello, 
Pitigliano, Massa Marittima  –) made by each patient. 
These data derived from the archives containing the 
flows of the hospital discharge records and accesses to 
ER, sent to the Region and then to the National Health 
System. We focused especially on the group of accesses 
to ER and hospitalizations related to bleeding, occurred 
within 4 months after the prescription of the anticoagu-
lant. In fact, the daily dose of this kind of therapy varies 
a lot and could be interrupted for surgery (even for mi-
nor surgery). So we estimated, by default, the maximum 
time between two prescriptions (sometimes 2 packs for 
each prescription) in 4 months: so considered the time 
span was from January 2012 to April 2013.
For each hospitalization the information we recorded 
were the date of admission and discharge diagnosis. In 
the hospital discharge records all the diagnoses are codi-
fied with the code ICD IX, so we considered all the diag-
noses containing the words “hemorrhage” and its deriva-
tives and “anemia” and its derivatives.
For each access to ER we recorded the date, time of stay, 
diagnosis and outcome. Diagnoses related to the access-
es to the ER are not codified using ICD IX, so we con-
sidered all the diagnoses related to bleedings in progress, 
previous or chronic. 
The results were organized in a database and then ex-
ported for statistical analysis. The collected data were 
processed using the software Stata® SE, version 12.1 
(StataCorp, College Station, Texas, USA). The level of 
significance was set at p < 0.05.
Results
From the pharmaceutical prescriptions database we ex-
tracted 4368 patients who received at least two prescrip-
tions of VKAs in 2012; 2304 (52.74%) were men.
3684 patients (84.34% of the entire sample) were > 65 
years old, 1889 were men (51.3%). The average age was 
78.2 years (79.2 for women CI 95% 78.9-79.5; and 77.2 
for men CI 95% 76.9-77.5). 
Accesses to Emergency Rooms
261 (7.1%) patients visited the emergency room for 
bleeding; 37 (1%) for intracranial bleeding. Patients 
who accessed to ER were represented especially by men 
(7.9%): women were the 6.2%, and this difference was 
statistically different (p  <  0.05). The average time of 
stay in ER was 349 minutes (CI 95% 296.1-402.2); for 
women 385 minutes (CI 95% 295.0-476.4); for men 325 
minutes (CI 95% 260.5-389.8). 
Table  I shows the principal diagnoses recorded during 
the visits to ER.
Admissions to hospital
The admissions to hospital were 96 (2.6%); 42 (1.1%) 
were admitted to hospital with a diagnosis of major vas-
Tab. I. Accesses to ER.
Diagnosis Percentage (%)
Epistaxis 24
Cerebral hemorrhage 11
Anemia 14
Conjunctival hemorrhage 9
Hematuria 11
Rectorragy 6
Other bleeding 25
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cular event. There is not any statistically significant dif-
ference in the admission to hospital or in the accesses to 
ER due to the prescribed medication (warfarin or aceno-
coumarol).
53 patients (20.3%), accessed to the ER more than one 
time. The 11.5% was admitted to the hospital more than 
one time. 
Figure 1 shows the principal diagnoses recorded during 
the admissions to hospital in the considered time-span.
Discussion and conclusions
The 84.34% of the sample analyzed in our study was > 65 
years old, and was represented especially by men (51.3%) 
with an average age of 78.2 years. These data are partial-
ly in line with those found by Kim et al. in 2010: of the 
2346 subjects enrolled in their study to evaluate the hospi-
talization costs associated with warfarin-related bleeding 
events, 1804 were females (77%) and about two-thirds of 
the subjects were over the age of 75 years (< 70 years: 
12%, 71-75 years: 23%, 76-80 years: 28%, 81-85 years: 
25%, ≥ 86 years: 12%) [19].
In our study the accesses to the emergency room for 
bleeding (7.1%) were higher than the admissions 
to hospital (2.6%). In a meta analysis conducted 
in 2012  [15] it was showed that during the initial 3 
months of anticoagulation, the rate of major bleeding 
was 2.06% (CI 2.04% to 2.08%) and the rate of fatal 
bleeding was 0.37% (CI 0.36% to 0.38%). The rate of 
intracranial bleeding was 1.48% (CI 1.40% to 1.56%). 
Chai-Adisaksopha et al. in 2014 showed in their study 
that total bleeding occurred in 30.42% patients treated 
with vitamin K antagonists (VKAs), a lower percent-
age compared to the 24.86% of patients treated with 
Target-Specific Oral Anticoagulants (TSOACs); how-
ever, major gastrointestinal bleeding occurred in 2.09% 
of patients treated with TSOACs and 1.70% of patients 
treated with VKAs [20]. Dale et al. in fact showed that 
warfarin is associated with greater thrombin suppres-
sion in the brain and pathological thrombosis at sites of 
atherosclerotic plaque disruption [21].
The problem of bleeding after the therapy with VKAs 
is important for the costs that this phenomenon cre-
ates in the National Health System. Sameer R. Ghate 
et al.  [22] showed that during the 12 months after the 
treatment there was a significantly higher increase of 
major gastrointestinal or intracranial bleeding event and 
consequently of hospitalizations, hospital days, and ER 
visits. In the 12 months after the warfarin start date, the 
mean adjusted annual costs obtained from the regression 
model were $42,574, $36,571, $22,824, and $22,507 
for subjects with intracranial bleeding, major gastroin-
testinal bleeding, minor gastrointestinal bleeding, and 
no bleeding, respectively [22]. The mean length of stay 
was 7.8 days (SD: 7.1). For the entire cohort, warfarin-
related bleeding resulted in an average increased cost of 
hospitalization of $508.30 per warfarin user [19].
The most important limit of our study is that the study 
sample is not representative of the Italian population: in 
fact our sample is composed by patients older than 65 
years and treated with VKAs; furthermore, our sample is 
composed only by patients living in Grosseto Province. 
Our study is limited to 2013 because the organizational 
changes in the Local Health Units, led to the fusion of 
three Local Health Unit (Grosseto, Siena and Arezzo) 
in a unique Unit, with the following fusion of the data-
bases, which is not totally finished yet. So the previous 
databases have not been implemented in the same way, 
therefore it is impossible to repeat the analysis with up-
dated data, although we think that significant differences 
would not be found. 
It could be interesting to complete our study enlarging 
the sample size, and enrolling patients living in other 
provinces or in other regions in Italy, with a lower age 
and treated also with TSOACs. We encourage other col-
leagues to conduct with us a multicentre study in order 
to identify significant differences that could influence 
the costs for the National Health System and evalu-
ate the real cost-effectiveness of anticoagulant therapy. 
Moreover, it would be interesting to investigate the qual-
ity of life [23-25] of patients treated with the two classes 
of drugs and to evaluate the impact of these therapies on 
this non-economic aspect of healthcare. 
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